Advertisement
UK markets close in 1 hour 32 minutes

  • FTSE 100

    8,064.75
    +19.94 (+0.25%)
     

  • FTSE 250

    19,766.07
    -33.65 (-0.17%)
     

  • AIM

    754.80
    -0.07 (-0.01%)
     

  • GBP/EUR

    1.1634
    +0.0006 (+0.05%)
     

  • GBP/USD

    1.2441
    -0.0011 (-0.09%)
     

  • Bitcoin GBP

    52,971.01
    -479.79 (-0.90%)
     

  • CMC Crypto 200

    1,429.76
    +5.66 (+0.40%)
     

  • S&P 500

    5,078.74
    +8.19 (+0.16%)
     

  • DOW

    38,481.36
    -22.33 (-0.06%)
     

  • CRUDE OIL

    82.79
    -0.57 (-0.68%)
     

  • GOLD FUTURES

    2,331.60
    -10.50 (-0.45%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,143.13
    +5.48 (+0.03%)
     

  • CAC 40

    8,124.80
    +19.02 (+0.23%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth

Daniel Collins
Updated
Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth

In 4Q17, Novo Nordisk’s (NVO) hemophilia drugs NovoSeven and NovoEight generated revenues of 2.4 billion Danish kroner and 274 billion Danish kroner, respectively. That’s a ~3% and 1% YoY (year-over-year) growth in local currency.

Continue reading